About this item:

29 Views | 50 Downloads

Author Notes:

Correspondence to: Pan Pantziarka. Email: anticancer.org.uk@gmail.com

This work would not be as extensive without the contribution of multiple collaborators, researchers and clinicians who share our interest in drug repurposing.

We are grateful to Richard Kast, Andrew Wilcock, Michael Jameson, Lars Søraas, Nicolas André, Albrecht Reichle, Richard Sullivan, Bjørn Tore Gjertsen, Peter Nygren, our colleagues at the Anticancer Fund and the team at ecancermedicalscience … and many others who have shared their findings with us to make this list as complete as possible.

The authors declare that they have no competing interests.

All the authors are associated with not for profit organisations that aim to repurpose drugs for oncology treatments.

VPS is also a scientific advisory board member of Berg Health and Mitra Biotech.

Subjects:

Keywords:

  • ReDO project
  • cancer drugs
  • drug repurposing
  • online database
  • repositioning

Redo_DB: The repurposing drugs in oncology database

Show all authors Show less authors

Tools:

Journal Title:

ecancermedicalscience

Volume:

Volume 12

Publisher:

, Pages 886-886

Type of Work:

Article | Final Publisher PDF

Abstract:

Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project.org/db/).

Copyright information:

© The authors.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Creative Commons License

Export to EndNote